Company: DARE
Filing Date: 2025-06-12
Form Type: DEFA14A
Source: 0001641172-25-014903
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-06-12
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934</div>

| Filed                
 by the Registrant ☒  |     |                                                                   | Filed                                  
 by a Party other than the Registrant ☐ |
| Check                
 the appropriate box: |     |                                                                   |                                        |
| ☐                    |     | Preliminary                                                       
 Proxy Statement                                                   |                                        |
| ☐                    |     | Confidential,                                                     
 for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |                                        |
| ☐                    |     | Definitive                                                        
 Proxy Statement                                                   |                                        |
| ☒                    |     | Definitive                                                        
 Additional Materials                                              |                                        |
| ☐                    |     | Soliciting                                                        
 Material under § 240.14a-12                                       |                                        |

<div align='center'>DARÉ BIOSCIENCE, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ |     | No                                                                                              
 fee required                                                                                    |
| ☐ |     | Fee                                                                                             
 paid previously with preliminary materials                                                      |
| ☐ |     | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

Explanatory Note

On June 12, 2025, Daré Bioscience, Inc. (the “Company”) issued the following press release, which contains information relating to the Company’s 2025 annual meeting of stockholders.

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Meeting to Reconvene on Wednesday, July 9, 2025

SAN DIEGO, CA, June 12, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women’s health a priority, today announced that the company’s 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business